Implementing the EffTox dose-finding design in the Matchpoint trial

Research output: Contribution to journalArticle

Standard

Implementing the EffTox dose-finding design in the Matchpoint trial. / Brock, Kristian; Billingham, Lucinda; Copland, Mhairi; Siddique, Shamyla; Sirovica, Mirjana; Yap, Christina.

In: BMC Medical Research Methodology, Vol. 17, 112, 20.07.2017.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{e81f62911994428aa6a29855770d9bd2,
title = "Implementing the EffTox dose-finding design in the Matchpoint trial",
abstract = "BackgroundThe Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic transformation phase. The dose should be both tolerable and efficacious. This paper describes our experience implementing EffTox in the Matchpoint trial.MethodsEffTox is a Bayesian adaptive dose-finding trial design that jointly scrutinises binary efficacy and toxicity outcomes. We describe a nomenclature for succinctly describing outcomes in phase I/II dose-finding trials. We use dose-transition pathways, where doses are calculated for each feasible set of outcomes in future cohorts. We introduce the phenomenon of dose ambivalence, where EffTox can recommend different doses after observing the same outcomes. We also describe our experiences with outcome ambiguity, where the categorical evaluation of some primary outcomes is temporarily delayed.ResultsWe arrived at an EffTox parameterisation that is simulated to perform well over a range of scenarios. In scenarios where dose ambivalence manifested, we were guided by the dose-transition pathways. This technique facilitates planning, and also helped us overcome short-term outcome ambiguity.ConclusionsEffTox is an efficient and powerful design, but not without its challenges. Joint phase I/II clinical trial designs will likely become increasingly important in coming years as we further investigate non-cytotoxic treatments and streamline the drug approval process. We hope this account of the problems we faced and the solutions we used will help others implement this dose-finding clinical trial design.",
keywords = "EffTox, Phase I/II, Dose-finding, Efficacy, Toxicity, CML",
author = "Kristian Brock and Lucinda Billingham and Mhairi Copland and Shamyla Siddique and Mirjana Sirovica and Christina Yap",
year = "2017",
month = jul,
day = "20",
doi = "10.1186/s12874-017-0381-x",
language = "English",
volume = "17",
journal = "BMC Medical Research Methodology",
issn = "1471-2288",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - Implementing the EffTox dose-finding design in the Matchpoint trial

AU - Brock, Kristian

AU - Billingham, Lucinda

AU - Copland, Mhairi

AU - Siddique, Shamyla

AU - Sirovica, Mirjana

AU - Yap, Christina

PY - 2017/7/20

Y1 - 2017/7/20

N2 - BackgroundThe Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic transformation phase. The dose should be both tolerable and efficacious. This paper describes our experience implementing EffTox in the Matchpoint trial.MethodsEffTox is a Bayesian adaptive dose-finding trial design that jointly scrutinises binary efficacy and toxicity outcomes. We describe a nomenclature for succinctly describing outcomes in phase I/II dose-finding trials. We use dose-transition pathways, where doses are calculated for each feasible set of outcomes in future cohorts. We introduce the phenomenon of dose ambivalence, where EffTox can recommend different doses after observing the same outcomes. We also describe our experiences with outcome ambiguity, where the categorical evaluation of some primary outcomes is temporarily delayed.ResultsWe arrived at an EffTox parameterisation that is simulated to perform well over a range of scenarios. In scenarios where dose ambivalence manifested, we were guided by the dose-transition pathways. This technique facilitates planning, and also helped us overcome short-term outcome ambiguity.ConclusionsEffTox is an efficient and powerful design, but not without its challenges. Joint phase I/II clinical trial designs will likely become increasingly important in coming years as we further investigate non-cytotoxic treatments and streamline the drug approval process. We hope this account of the problems we faced and the solutions we used will help others implement this dose-finding clinical trial design.

AB - BackgroundThe Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic transformation phase. The dose should be both tolerable and efficacious. This paper describes our experience implementing EffTox in the Matchpoint trial.MethodsEffTox is a Bayesian adaptive dose-finding trial design that jointly scrutinises binary efficacy and toxicity outcomes. We describe a nomenclature for succinctly describing outcomes in phase I/II dose-finding trials. We use dose-transition pathways, where doses are calculated for each feasible set of outcomes in future cohorts. We introduce the phenomenon of dose ambivalence, where EffTox can recommend different doses after observing the same outcomes. We also describe our experiences with outcome ambiguity, where the categorical evaluation of some primary outcomes is temporarily delayed.ResultsWe arrived at an EffTox parameterisation that is simulated to perform well over a range of scenarios. In scenarios where dose ambivalence manifested, we were guided by the dose-transition pathways. This technique facilitates planning, and also helped us overcome short-term outcome ambiguity.ConclusionsEffTox is an efficient and powerful design, but not without its challenges. Joint phase I/II clinical trial designs will likely become increasingly important in coming years as we further investigate non-cytotoxic treatments and streamline the drug approval process. We hope this account of the problems we faced and the solutions we used will help others implement this dose-finding clinical trial design.

KW - EffTox

KW - Phase I/II

KW - Dose-finding

KW - Efficacy

KW - Toxicity

KW - CML

U2 - 10.1186/s12874-017-0381-x

DO - 10.1186/s12874-017-0381-x

M3 - Article

VL - 17

JO - BMC Medical Research Methodology

JF - BMC Medical Research Methodology

SN - 1471-2288

M1 - 112

ER -